Download the AbstractBooklet.

Day 1: Monday 20 November
Start End Type Name Title
08:30 09:00 Registration
Welcome and opening
Session Chair: Professor Simon Foote (ANU)
09:00 09:05 Welcome: Professor Simon Foote
09:05 09:15 Introduction: Professor Brian Schmidt VC ANU
09:15 9:50 Opening Alan Finkel (Australian Chief Scientist) Genome engineering technologies in the Australian science landscape: progresses and challenges
9:50 10:30 Morning Tea
Session 1: Revolutionising Cancer Research with CRISPR
Session Chair: James Doecke (CSIRO)
10:30 11:00 Invited Pilar Blancafort (Harry Perkins Institiute, UWA) Targeted epigenetic editing for reprograming of complex phenotypes in breast cancer
11:00 11:45 Keynote Laura Attardi (Stanford University, USA) Deconstructing the p53 Tumor Suppression Program Through Combined RNA interference and CRISPR Screening
11:45 12:15 Invited Susan Woods (University of Adelaide) Rapid, complex models of colorectal cancer: using CRISPR/Cas9 genome editing to target frequently altered genes
12:15 12:30 Selected talk Shinsuke Mizutani (WEHI)  Whole genome in vivo CRISPR/Cas9 screens identify novel tumour suppressor genes in Eµ-Myc lymphomagenesis
Sponsored Lunch session by Dharmacon

Session Chair: Kaylene Simpson (Petermac)

12:30 13:00  Break Lunch
13:00 14:00 Annaleen Vermeulen (Dharmacon)  Using CRISPR/Cas9 tools for gene knockout and transcriptional activation to understand gene function
Session 3: CRISPR/Cas9 advance editing techniques
Session Chair: Denis Bauer (CSIRO)
14:00 14:30 Organizer Gaetan Burgio (ANU) Improving HDR effciency for CRISPR/Cas9 editing in mice
14:30 14:45 Selected talk Andrew Kueh (WEHI)

The application of CRISPR/Cas9 technology in generating complex mouse models

14:45 15:00 Selected talk Aidan O’Brien (CSIRO) Predicting the HDR efficiency of CRISPR-Cas9
15:00 15:20  Break Afternoon Tea
Session 4: Cohort level analysis using CRISPR/Cas9 editing
Session Chair: Gaetan Burgio (ANU)
15:20 15:50 Keynote Danilo Maddalo (Novartis) Crispr/Cas9 in in vivo modeling and drug discovery
15:50 16:20 Organizer Marco Herold (WEHI) Using CRISPR/Cas9 to identify novel drug targets for cancer therapy
16:20 16:50 Invited Sean Grimmond (University of Melbourne) Global cancer cohorts efforts
16:50 17:05 Selected talk Predrag Kalajdzic (CMRI) The Vector and Genome Engineering Facility (VGEF): Customized service for your research needs
18:30 Conference dinner Monday 20 November at the National Arboretum Canberra
Day 2: Tuesday 21 November
         08:30    09:00     Registration
Session 5: Understanding and applying CRISPR/Cas9
Session Chair: Kaylene Simpson (Petermac)
09:00 09:15 Selected talk Nigel McMillian (Menzies Health Institute of Queensland) Using of gene editing to treat cancers both in vitro and in vivo
09:15  09:45 Organizer  Laurence Wilson (CSIRO)  Using machine learning to understand CRISPR-Cas9 activity
09:45 10:15 Invited Hugh Goold (Macquarie University) Yeast 2.0: Design, synthesis, and testing of a Eukaryotic genome
10:15 10:30 Organizer James Doecke (CSIRO)

What to expect from your CRIPSR experiment: Finding downstream effects adjacent to your primary target

10:30 10:50 Break Morning Tea
Session 6: CRISPR/Cas9 and Cancer
Session Chair: Gaetan Burgio (ANU) 
10:50 11:05 Selected talk Jai Rautela (WEHI) Gene-editing in immune checkpoint discovery
11:05 11:20 Selected talk Andrew Jarratt (WEHI) A whole genome CRISPR/Cas9 screen for regulators of JAK-STAT signalling reveals epigenetic control
11:20 11:35 Selected talk Jia-Nan Gon (WEHI) Investigating the Resistant Mechanisms to the BCL2 selective inhibitor Venetoclax in Multiple Myeloma using Genome-Scale CRISPR/Cas9 Knockout Screening
11:35 11:50 Selected talk Mark van Delft (WEHI) CRISPR/Cas9 screens reveal VDAC2 to be a critical regulator of BAX-mediated cell death and chemotherapeutic response
11:50 12:20 Invited Ross Hannan (ANU) Genome wide screens to develop new targets for cancer therapy
12:20 13:20 Lunch
Session 7: Show and Tell CRISPR/Cas9 Analysis
Session Chair: Denis Bauer (CSIRO)
13:20 14:00 Company pitches from: Millennium Science, Genesearch, Sigma, AGRF, Lonza, Scientifix, Biotools and Thermofisher
14:00 14:15 The Australian Phenomics Network (Dr Michael Dobbie, CEO)
Session 8: CRISPR/Cas9 Gene editing: Ethics and IP
Session Chair: Laurence Wilson (CSIRO)
14:15 14:45 Invited Sally Davis (Davies, Collison and Cave IP) CRISPR/Cas9: Innovation and Commercialisation in a Complex IP Environment
14:45 15:15 Invited Rachel Ankeny (University of Adelaide) CRISPR/Cas9 and bioethics
15:15 15:35 Break Afternoon Tea
Session 9: Genome editing in model systems
Session Chair: Marco Herold (WEHI)
15:35 16:05 Invited Yu Chang (BGI)

Advancing genome editing technology adoption with computational innovations.

16:05 16:35 Invited Greg Neely (University of Sydney) CRISPR/Cas9 high-throughput screening in Drosophila
16:35 17:05 Invited Leonie Quinn (ANU) The inexplicable tumour suppressor behaviour of FUBP1 in Oligodendroglioma
18:00 BBQ, Fellows Gardens, University House
Day 3: Wednesday 22 November
         08:30    09:00     Registration
Session 10: High Throughput Screening and Beyond Genome Editing
Session Chair: Denis Bauer (CSIRO)
9:00 9:30 Invited Ben Hayley (Genentech) CRISPR/a screening and techniques
9:30 10:00 Invited Ryan Lister (Harry Perkins Institute) Editing the epigenome
10:00 10:30 Organizer Kaylene Simpson (Peter McCallum, Meblourne) High throughput screening strategies
10:30 10:50  Break Morning Tea
Session 11: Bioinformatics/Biostatistics approaches to data from CRISPR/Cas9 editing
Session Chair: James Doecke (CSIRO)
10:50 11:35 Keynote Veera Baladandayuthapani (MD Anderson, USA) Biostatistics for finding relevant targets
11:35 12:05 Invited Gordon Smyth (WEHI) Using scRNA-seq to construct developmental lineage relationships in the mouse mammary gland
12:05 12:35 Invited Jean Yang (University of Sydney) Data analysis for cancer research
12:35 12:50 Closing remarks: Dr Denis Bauer (CSIRO)